LEO Pharma UK/IE’s talented and determined team are passionate about improving people’s lives. Our drive is not only in delivering novel treatments in dermatology (skin) and thrombosis (blood clots) that reach previously unmet needs, but also in creating programmes that empower people to think differently about their condition and take control. We believe in the power of sharing knowledge and open our minds to fresh thinking: We listen to the needs of patients and healthcare professionals and aim to develop innovative care solutions together that will make a real, tangible difference.
Our mission is to help people achieve healthy skin. We have been at the forefront of dermatological care for over half a century through pioneering treatments, raising the profile and awareness of the impact of living with skin conditions and championing high quality dermatology education.
“LEO Pharma, being a Foundation rather than a shares-dependent company, have been brilliant at supporting medical education for Dermatology Health Care Professionals. For example, LEO Pharma have sponsored the annual Psychodermatology UK Training for dermatology trainees. This course was originally over a weekend and then (after trainees’ feedback) converted to a two day course. It has run annually for the previous 12 years. The educational grants provided by LEO Pharma have been invaluable in supporting psychodermatology training when no such course existed.”
– Anthony Bewley, Consultant Dermatologist, Barts Health NHS Trust
Striking statistics including that 4,000 people per year in England die from Cancer Associated Thrombosis (CAT)1 and that Venous Thromboembolism is the second most common cause of death in patients with cancer2 are the reason that we continually drive to deliver effective thrombotic treatments. We also aim to provide resources as well as raise awareness of the importance of education on Cancer Associated Thrombosis (CAT).
References:1 APPTG Venous Thromboembolism (VTE) In Cancer Patients 2015, page 5
2 APPTG Venous Thromboembolism (VTE) In Cancer Patients 2015, page 6